2015 American Transplant Congress
Efficacy of Rituximab Sparing Protocol for ABO Incompatible Renal Transplant in Patients With Low Titers
[Introduction]Acute antibody mediated rejection (AMR) has been a major problem in ABO-incompatible kidney transplantation (ABOi-KTx), and currently mycophenolate mofetil and rituximab have been used to…2015 American Transplant Congress
Inhibition of Endogenous Memory CD8 T Cell Infiltration Into Cardiac Allografts Subjected to Prolonged Cold Ischemic Storage Is Required to Promote Long-Term Graft Survival
Endogenous memory CD8 T cells infiltrate MHC-mismatched cardiac allografts and produce IFN-γ in response to donor class І MHC within 24 hrs after graft reperfusion…2015 American Transplant Congress
Are AT1R Antibodies as Dangerous as HLA-DSAs in Renal Allografts?
Angiotensin II type 1 receptor antibodies (AT1Rab) have been associated with a significantly lower graft survival and a higher risk of acute rejection after kidney…2015 American Transplant Congress
DSA Monitoring in Kidney Transplant Recipients
Introduction: The development of DSA monitoring is a new technique to detect antibodies in kidney transplant recipients. Data has shown that development of DSA post…2015 American Transplant Congress
Mesenchymal Stem Cells (MSCs) Transfusion for Desensitization of Positive Lymphocyte Cross Match (LCM) or Panel Reactive Antibodies (PRA) Before Kidney Transplantation Outcome of 16 Cases
Immunomodulatory function of MSCs may correct positive PRA or LCM in highly-sensitized patients. We evaluate donor specific or 3rd party MSCs transfusion in 16 patients…2015 American Transplant Congress
Evaluation of Donor-Specific Antibodies Through 7 Years With Belatacept in BENEFIT and BENEFIT-EXT
1Emory University, Atlanta; 2Bristol-Myers Squibb, Lawrenceville.
Purpose: The development of donor-specific antibody (DSA) is linked to an increased risk of antibody-mediated rejection and graft failure. The 3 year intent-to-treat results from…2015 American Transplant Congress
Changes in Donor Specific Antibodies (DSA) First Year After Kidney Transplant (KTX): Implications for Graft Histology and Survival
Introduction. De novo DSA post-KTx is associated with high risk of chronic antibody mediated rejection (cAMR) and reduced graft survival. DSA changes during first year…2015 American Transplant Congress
Eculizumab as a Rescue Therapy for Rhinovirus-Induced Antibody Mediated Rejection After Incompatible Kidney Transplantation
Northwestern University, Chicago, IL.
Background: Despite being an effective strategy for overcoming ABO and HLA incompatibilities, desensitized kidney transplantation still has limitations. Early antibody mediated rejection (ABMR) may be…2015 American Transplant Congress
The Use of Bortezomib for Desensitization in ABO Incompatible and Positive Crossmatch Kidney Transplant
Introduction:ABO incompatible (ABOi) and positive crossmatch (PXM) living donor kidney transplantation is a life-saving alternative to dialysis. A variety of protocols exist utilizing plasmapheresis (PP)…2015 American Transplant Congress
LFA-1 Is Crucial for Germinal Center Reconstruction After T cell Depletion and IL-21 Biased Antibody-Mediated Rejection
1Surgery, Emory Transplant Center, Atlanta, GA; 2Surgery, Duke University, Durham, NC.
[Background] Lymphocyte depletion prior to transplantation is beneficial in reducing initial maintenance immunosuppression in transplantation. However, despite its excellent efficacy in controlling T cell mediated…
- « Previous Page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- …
- 57
- Next Page »